RU2000131217A - HYBRID PROTEIN FOR INHIBITING MASTOCYTE DEGRANULATION AND ITS APPLICATION - Google Patents

HYBRID PROTEIN FOR INHIBITING MASTOCYTE DEGRANULATION AND ITS APPLICATION

Info

Publication number
RU2000131217A
RU2000131217A RU2000131217/04A RU2000131217A RU2000131217A RU 2000131217 A RU2000131217 A RU 2000131217A RU 2000131217/04 A RU2000131217/04 A RU 2000131217/04A RU 2000131217 A RU2000131217 A RU 2000131217A RU 2000131217 A RU2000131217 A RU 2000131217A
Authority
RU
Russia
Prior art keywords
protein
protease
fragment
basophils
toxin
Prior art date
Application number
RU2000131217/04A
Other languages
Russian (ru)
Other versions
RU2214420C2 (en
Inventor
Ханс БИГАЛЬКЕ
Йюрген ФРЕВЕРТ
Original Assignee
Биотекон Гезелльшафт Фюр Биотехнологише Энтвиклунг Унд Консультинг Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биотекон Гезелльшафт Фюр Биотехнологише Энтвиклунг Унд Консультинг Мбх filed Critical Биотекон Гезелльшафт Фюр Биотехнологише Энтвиклунг Унд Консультинг Мбх
Publication of RU2000131217A publication Critical patent/RU2000131217A/en
Application granted granted Critical
Publication of RU2214420C2 publication Critical patent/RU2214420C2/en

Links

Claims (6)

1. Гибридный белок, содержащий: (I) белок, по существу известный, связывающийся с мастоцитами и/или базофилами и/или поглощаемый этими клетками по существу известным образом, (II) протеазу, по существу известную, расщепляющую один или несколько белков аппарата секреции мастоцитов и/или базофилов, или состоящий из них.1. A fusion protein comprising: (I) a protein, essentially known, that binds to mast cells and / or basophils and / or is absorbed by these cells in a manner known per se, (II) a protease, essentially known, that cleaves one or more proteins of the secretion apparatus mastocytes and / or basophils, or consisting of them. 2. Гибридный белок, содержащий: (I) белок, связывающийся с мастоцитами и/или базофилами и/или поглощаемый этими клетками, причем этот белок (I) выбран из группы, состоящей из: иммуноглобулина Е (IgE), фрагмента IgE, в частности Fc-фрагмента IgE, антитела против IgE-рецептора мастоцитов и/или базофилов, фрагмента антитела против IgE-рецептора мастоцитов и/или базофилов, в частности Fab-фрагмента, антитела против мастоцит-специфического калиевого канала и неактивного, но связывающего мастоцит-дегранулирующего (MCD) пептида, и (II) протеазу, в частности протеазу, по существу известную, расщепляющую один или несколько белков аппарата секреции мастоцитов и/или базофилов, или состоящий из них. 2. A hybrid protein containing: (I) a protein that binds to mast cells and / or basophils and / or is absorbed by these cells, moreover, this protein (I) is selected from the group consisting of: immunoglobulin E (IgE), an IgE fragment, in particular IgE Fc fragment, anti-mastocyte and / or basophil anti-IgE receptor antibody, anti-mast cell and / or basophil anti-IgE antibody fragment, in particular a Fab fragment, anti-mast cell specific potassium channel antibody and inactive but binding mast cell degranulating ( MCD) peptide, and (II) protease, in particular protease , essentially known, cleaving one or more proteins of the apparatus for the secretion of mast cells and / or basophils, or consisting of them. 3. Гибридный белок, содержащий: (I) белок, в частности белок, по существу известный, связывающийся с мастоцитами и/или базофилами и/или поглощаемый этими клетками, в частности по существу известным образом, и (II) протеазу, расщепляющую один или несколько белков аппарата секреции мастоцитов и/или базофилов, причем эта протеаза (II) выбрана из группы, состоящей из: легкой цепи токсина Clostridium botulinum, в частности токсинов типа А, В, С1, D, E, F и G, каталитически активного фрагмента легкой цепи токсина Clostridium botulinum, в частности токсина типа А, В, С1, D, Е, F и G, легкой цепи столбнячного токсина (TeNT), каталитически активного фрагмента легкой цепи столбнячного токсина, протеазы иммуноглобулина A (IgA) Neisseria gonorrhoeae, и каталитического домена протеазы IgA Neisseria gonorrhoeae, или состоящий из них. 3. A fusion protein comprising: (I) a protein, in particular a protein, essentially known, that binds to mast cells and / or basophils and / or is absorbed by these cells, in particular in a substantially known manner, and (II) a protease that cleaves one or several proteins of the apparatus for the secretion of mast cells and / or basophils, and this protease (II) is selected from the group consisting of: the light chain of the toxin Clostridium botulinum, in particular toxins of type A, B, C1, D, E, F and G, a catalytically active fragment the light chain of the toxin Clostridium botulinum, in particular the type A, B, C1, D, E, F and G toxin, a tetanus toxin chain (TeNT) chain, a catalytically active fragment of a tetanus toxin light chain, immunoglobulin A protease (IgA) Neisseria gonorrhoeae, and or consisting of a catalytic domain of IgA Neisseria gonorrhoeae protease. 4. Гибридный белок по п. 2 или 3, отличающийся тем, что белок (I) выбран из группы в соответствии с п. 2, а протеаза (II) выбрана из группы в соответствии с п. 3. 4. A hybrid protein according to claim 2 or 3, characterized in that the protein (I) is selected from the group according to claim 2, and the protease (II) is selected from the group according to claim 3. 5. Гибридный белок по п. 4, отличающийся тем, что N-концевой участок тяжелой цепи соответствующего токсина (HN фрагмент) или его фрагмент может представлять собой часть гибридного белка, в дополнение к легкой цепи токсина Clostridium botulinum или столбнячного токсина.5. The hybrid protein according to claim 4, characterized in that the N-terminal portion of the heavy chain of the corresponding toxin (H N fragment) or its fragment may be part of a hybrid protein, in addition to the light chain of the toxin Clostridium botulinum or tetanus toxin. 6. Применение гибридного белка по любому из пп. 1-5 для ингибирования дегрануляции мастоцитов. 6. The use of a hybrid protein according to any one of paragraphs. 1-5 to inhibit mast cell degranulation.
RU2000131217/04A 1998-05-13 1999-05-12 Hybrid protein for inhibition of degranulation of mastocytes and its application RU2214420C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
DE19821285.2 1998-05-13

Publications (2)

Publication Number Publication Date
RU2000131217A true RU2000131217A (en) 2003-01-27
RU2214420C2 RU2214420C2 (en) 2003-10-20

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000131217/04A RU2214420C2 (en) 1998-05-13 1999-05-12 Hybrid protein for inhibition of degranulation of mastocytes and its application

Country Status (22)

Country Link
EP (1) EP1084146B1 (en)
JP (1) JP4549533B2 (en)
KR (1) KR100580541B1 (en)
CN (1) CN1241945C (en)
AT (1) ATE227739T1 (en)
AU (1) AU755513B2 (en)
BR (1) BR9910359A (en)
CA (1) CA2331274C (en)
CU (1) CU22997A3 (en)
CZ (1) CZ294376B6 (en)
DE (1) DE59903410D1 (en)
DK (1) DK1084146T3 (en)
ES (1) ES2187200T3 (en)
HK (1) HK1036994A1 (en)
HU (1) HUP0103601A3 (en)
IL (2) IL139478A0 (en)
MX (1) MXPA00011148A (en)
NO (1) NO328361B1 (en)
PL (1) PL201879B1 (en)
PT (1) PT1084146E (en)
RU (1) RU2214420C2 (en)
WO (1) WO1999058571A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
MXPA03000014A (en) * 2000-06-28 2004-09-13 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals).
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (en) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 Peptide for activating mast cell and immunomodulator comprising the same
US20110171191A1 (en) 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
EP2318524B1 (en) * 2008-07-31 2016-02-24 Total Marketing Services Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (en) * 2010-05-27 2014-05-14 四川大学 Recombinant IgE-Fc-anti EGFR single chain variable fragment fusion protein, its preparation method and its application
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
KR20230155007A (en) 2021-03-30 2023-11-09 입센 바이오팜 리미티드 Catalytically Inactive Clostridial Neurotoxin for Treatment of Pain & Inflammatory Disorders
JP2024513191A (en) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド Treatment of pain and inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (en) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Use of 2-methoxyestradiol in the treatment of mastocytosis
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Similar Documents

Publication Publication Date Title
RU2000131217A (en) HYBRID PROTEIN FOR INHIBITING MASTOCYTE DEGRANULATION AND ITS APPLICATION
CA2331274A1 (en) Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
Paul et al. Peptidolytic monoclonal antibody elicited by a neuropeptide.
DE60234094D1 (en) SPECIFIC TIE PROTEINS AND ITS USE
JP2005537809A5 (en)
EP2172486A3 (en) Monoclonal antibody against a prion protein and its use for the detection of prions
DE69434612D1 (en) Monoclonal antibodies to recombinant stratum corneum chymotryptic enzyme (SCCE)
DE60131468D1 (en) HIGH-THROUGHPUT ASSAYS FOR PROTEOLYTIC ACTIVITIES OF CLOSTRIDIUM NEUROTOXINES
KR970707153A (en) Cathepsin 02 Protease (CATHEPSIN 02 PROTEASE)
EP1989549A1 (en) Protease detection
TR200504220T2 (en) Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
ATE168779T1 (en) IMMUNOASSAY FOR DETECTING COLLAGEN TYPE I OR COLLAGEN FRAGMENTS THEREOF
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
WO2005016232A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
HUP0101987A2 (en) The induction of antibiotic peptides by lait (scd14) protein
ATE309363T1 (en) HYBRID TOXINS OF BACILLUS THURINGIENSIS
Krivi et al. Purification of recA-based fusion proteins by immunoadsorbent chromatography. Characterization of a major antigenic determinant of Escherichia coli recA protein.
Inouye et al. Pepsin digestion of a mouse monoclonal antibody of IgG1 class formed F (ab′) 2 fragments in which the light chains as well as the heavy chains were truncated
DE59709495D1 (en) Antibodies and immunoassay for the detection of MIA
RU98106859A (en) A NEW ANTIBODY, A RENIN ACTIVITY COMPOUND CONTAINING A NEW ANTIBODY, AND A REAGENT FOR DETERMINING PROENININE USING A NEW ANTIBODY
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
Li et al. Proteolytic components of serum IgG preparations
Estêvão-Costa et al. Neutralization of the hemorrhagic activity of Bothrops and Lachesis snake venoms by a monoclonal antibody against mutalysin-II
DE69502095D1 (en) SOLID PHASE IMMUNOASSAY FOR DETECTING INHIBITORS FROM A PROTEOLYTIC ENZYME
Siigur et al. Cross-reactivities of polyclonal antibodies against lebetase, fibrinolytic enzyme of Levantine viper (Vipera lebetina) venom